Clinical Research Progress on Transformed Lymphoma -Review.
10.7534/j.issn.1009-2137.2016.04.050
- Author:
Bing-Jie WANG
1
;
Xi-Nan CEN
2
;
Han-Yun REN
1
Author Information
1. Department of Hematology, Peking University First Hospital, Beijing 100034, China.
2. Department of Hematology, Peking University First Hospital, Beijing 100034, China.E-mail：cenxn@aliyun.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Humans;
Lymphoma, Non-Hodgkin
- From:
Journal of Experimental Hematology
2016;24(4):1232-1236
- CountryChina
- Language:Chinese
-
Abstract:
Histologic transformation (HT) is a frequent event in the clinical course of patients with indolent lymphoma with dismal outcome. The diagnosis of HT is based on clinical manifestation, PET-CT and pathologic biopsy, and the latter is a golden standard for HT. There are contradictory data about the impact of initial management on the risk of transformation. Patients who present with HT did not receive R-CHOP or chemotherapy-naive, should receive this regimen. For the subset of patients received R-CHOP prior to HT, the second line chemotherapy for DLBCL should be adopted. Consolidation with HDT-ASCT should be considered for the suitable young patients. The radio-immunotherapy and novel drugs showed a bright perspective for the patients with HT.
